Assessment of microbiota in the gut and upper respiratory tract associated with SARS-CoV-2 infectionOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study assessed how SARS-CoV-2 infection alters microbiota in the upper respiratory tract and gut across disease severity. It compared microbial composition and function between patients and healthy donors. Samples were pharyngeal swabs, sputum, and feces. Researchers used a metatranscriptomic RNA-seq strategy to capture both microbial and viral sequences from each sample. Taxonomy came from Kraken2, functions from HUMAnN2 and LEfSe, and community differences from PERMANOVA on Bray-Curtis distances.
Who was studied?
The cohort was 203 hospitalized COVID-19 patients and 31 healthy donors, after quality filtering. Patients were classified as mild, moderate, or severe by Chinese national guidelines. Analysis used 521 patient samples and 94 donor samples from three body sites: pharyngeal swabs, sputum, and feces. Patients were enrolled at Beijing Ditan Hospital from January to April 2020. The first sample per patient within 14 days of symptom onset was used to profile composition and function.
What were the most important findings?
Microbial composition was significantly affected by disease severity in all three sample types. Shannon diversity fell in pharyngeal and sputum samples, but gut alpha diversity did not change. Beta diversity separated patients from controls in all sites (p<0.001). Gut microbiota was more dispersed and, uniquely, its alteration was directly associated with SARS-CoV-2 abundance. Patient guts lost carbohydrate metabolism and short-chain-fatty-acid-generating genes. Airway microbiota carried enriched stress, toxin, and multidrug-efflux genes, signaling a high antibiotic-resistance risk.
What are the greatest implications of this study?
The results show respiratory and gut microbiota respond differently to SARS-CoV-2, with the gut more sensitive to viral load and more variable across patients. This refines how dysbiosis relates to COVID-19. Enriched airway resistance and toxin genes argue for careful, precise antibiotic use to limit resistance and support microbial recovery. Sampling gaps, few severe fecal samples, and no long-term follow-up limit conclusions, and observed associations do not prove the virus caused each microbial change.